Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBP-B
- Development stage
- Preclinical
- Lead developer
- Kannavis Biotech
- Modality
- Peptides
01
Overview
CBP-B is a preclinical-stage peptide-type immune-system anticancer drug candidate being developed by CanBas. It is part of the company's pipeline of next-generation immunotherapies designed to modulate the immune system to target cancer cells. The specific molecular target and mechanism of action for CBP-B have not been publicly disclosed. The drug candidate is currently in the optimization phase of preclinical development.
Beyond the preview
Go deeper on CBP-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBP-B.